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Abstract
Background and Objective Semaglutide is a glucagon-like
peptide-1 analogue in development for the once-weekly
treatment of type 2 diabetes mellitus. Its effect on the rate
and extent of absorption of concomitant oral medications
(metformin, warfarin, atorvastatin and digoxin) was eval-
uated in healthy subjects.
Methods Subjects received metformin (500 mg twice daily
for 3.5 days), warfarin (25 mg, single dose), atorvastatin
(40 mg, single dose) or digoxin (0.5 mg, single dose)
before and with subcutaneous semaglutide treatment at
steady state (1.0 mg). Lack of drug–drug interaction was
concluded if the 90% confidence intervals for the area
under the plasma concentration–time curve ratio before and
with semaglutide were within a pre-specified interval
(0.80–1.25).
Results Overall, metformin, warfarin, atorvastatin and
digoxin pharmacokinetics were not affected to a clinically
relevant degree with semaglutide co-administration. Esti-
mated area under the plasma concentration–time curve
ratios for all concomitant medications before and with
semaglutide treatment were within the pre-specified inter-
val. In addition, semaglutide did not affect maximum
plasma concentration of concomitant medications to a
relevant degree. Furthermore, no clinically relevant change
in international normalised ratio response to warfarin was
observed with semaglutide co-administration. Most
adverse events with semaglutide treatment were mild or
moderate. Adverse events with semaglutide and co-
administered medication were comparable to those repor-
ted during treatment with semaglutide alone, and were
mostly gastrointestinal related.
Conclusions No clinically significant pharmacokinetic or
pharmacodynamic interactions were identified and no new
safety issues observed with combined treatment with
semaglutide. This suggests that no dose adjustments should
be required when semaglutide is administered concomi-
tantly with these medications.
Key Points
Semaglutide did not cause any clinically significant
changes in the area under the plasma concentration–
time curve of metformin, warfarin, atorvastatin or
digoxin. Furthermore, semaglutide did not produce a
clinically significant change in the anticoagulant effect
of warfarin (as measured by changes in international
normalised ratio response) in healthy subjects.
Metformin, warfarin, atorvastatin and digoxin were
well tolerated in combination with semaglutide
1.0 mg, and no new safety issues were identified.
On the basis of these findings, these medications can
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A range of pharmacotherapies, in addition to lifestyle
changes, are available for the treatment of type 2 diabetes
mellitus (T2D). These include both oral and
injectable treatment options [1]. Owing to the progressive
nature of the disease, most patients ultimately require a
combination of pharmacological therapies to achieve gly-
caemic control [1–3]. Furthermore, although glucose con-
trol remains a central objective, it should be managed in the
context of a comprehensive cardiovascular (CV) risk factor
reduction programme, including smoking cessation, blood
pressure control, lipid management and antiplatelet therapy
[1]. Warfarin, digoxin and atorvastatin are indicated to
prevent and treat CV disease and are commonly prescribed
in patients with T2D who have a CV condition. Warfarin is
a widely used anticoagulant to reduce the risk of
thromboembolism [4]. Digoxin is used to treat atrial fib-
rillation, and atorvastatin is a lipid-lowering drug used to
treat patients with high cholesterol and to lower the risk of
CV disease in patients who are at an increased risk of heart
disease [5, 6]. Hence, many individuals with T2D and co-
morbidities, such as CV disease, may be taking multiple
medications, which may have an increased risk of drug
interactions [7].
One class of agents that is available for managing T2D
is the glucagon-like peptide-1 receptor agonists (GLP-
1RAs). In addition to their anti-hyperglycaemic effects,
these agents have been associated with CV protection in
two large CV outcome trials [8, 9]. Semaglutide is a GLP-1
analogue suitable for once-weekly administration, and is in
development for the treatment of T2D. Structurally, it has
94% homology to native GLP-1, but with important
structural modifications that make semaglutide suitable for
once-weekly subcutaneous administration, with fully
retained potency [10].
A previous study has shown that semaglutide is meta-
bolised prior to excretion, with semaglutide-related mate-
rial excreted in both urine and faeces (only 3% elimination
of intact semaglutide in urine) [11]. In addition, cyto-
chrome P450 (CYP) enzymes and transporters are not
expected to be inhibited or induced by semaglutide [12].
However, similarly to native GLP-1, semaglutide delays
gastric emptying during the first hour after a meal [13]. A
delay in gastric emptying could potentially alter the gas-
trointestinal (GI) absorption kinetics of concomitantly
administered therapies, thereby requiring dose adjustment.
Two studies were carried out in healthy subjects to
investigate the effects of semaglutide on the pharmaco-
kinetics of four therapies that are commonly co-administered
with GLP-1RAs [14–16] and are characterised by differing
properties of solubility and intestinal permeability [17].
Study 1 evaluated the effect of semaglutide 1.0 mg at
steady state on the pharmacokinetics of concomitant met-
formin and warfarin. The pharmacodynamic (PD) profile of
concomitant warfarin was also investigated. Metformin has
high solubility and low permeability, and is a widely used
dimethylbiguanide for the treatment of T2D. It is absorbed
in the small intestine and has an oral bioavailability of
50–60% [18]. The absorption of metformin decreases with
food, and may be altered when co-administered with
compounds affecting gastric emptying [19]. Peak plasma
concentrations of single-dose metformin occur 2–3 h after
dosing [20]. Warfarin has high permeability and high/low
solubility properties and is completely absorbed after oral
administration, with a peak concentration occurring after
2–6 h [21, 22]. Warfarin comprises two enantiomers, one
of which (R-warfarin) is metabolised by CYP1A2 and
CYP3A4, while the other (S-warfarin; five times more
potent than R-warfarin) is primarily metabolised by
CYP2C9 [23].
Study 2 evaluated the effect of semaglutide on the
pharmacokinetics of, respectively, concomitant atorvas-
tatin and digoxin. Atorvastatin has low solubility and high
permeability, and shows complete intestinal absorption
when orally administered, but its systemic bioavailability is
only 14% as it is subject to first-pass metabolism in the gut
and liver. Atorvastatin is metabolised by CYP3A4, and
drug–drug interactions with inhibitors of this system have
been demonstrated [24]. Digoxin has low solubility and
low permeability; it is incompletely (70%) absorbed from
the GI tract and attains its maximum effect 6 h after oral
dosing [5, 16]. Both warfarin and digoxin have a narrow
therapeutic window, thus there is a relatively high possi-
bility of drug–drug interactions. The purpose of these
studies was to assess whether semaglutide altered the
exposure of co-administered drugs commonly prescribed




Male and female adults were eligible for inclusion if
they met the following criteria: healthy; 18–55 years of
age at the time of signing informed consent; body mass
index 23.0–30.0 kg/m2 (Study 1) or 20.0–30.0 kg/m2
(Study 2); and glycosylated haemoglobin\6.5%. Key
exclusion criteria included: any clinically significant
disease history or systemic or organ disease; use of
prescription or non-prescription systemic or topical
medicinal products.
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2.2 Study Design and Treatment
Two open-label, one-sequence, crossover clinical pharma-
cology studies investigated the effect of once-weekly
subcutaneous semaglutide 1.0 mg steady state on the
pharmacokinetics of metformin, warfarin, atorvastatin and
digoxin, and the pharmacodynamics of warfarin
(NCT02022254, NCT02243098). Semaglutide was
administered subcutaneously once weekly in escalating
doses of 0.25 mg (4 weeks), 0.5 mg (4 weeks) and 1.0 mg
(4 weeks, to steady state). Dosing was continued for an
additional 2 weeks to ensure drug–drug interactions were
assessed at semaglutide steady state (Fig. 1). Interaction
assessments [pharmacokinetic (PK) profiles] were carried
out during in-house visits both before and with semaglutide
treatment (1.0 mg).
Two drugs were evaluated in each of the trials, separated
by a 7-day washout, the length of which was based on the
elimination half-life (t1/2) of metformin (5–6 h, in Study 1)
or atorvastatin (14 h; 20–30 h for metabolites, in Study 2)
and the semaglutide dosing interval. Pharmacokinetic
evaluations for atorvastatin were carried out before
digoxin, as the t1/2 of digoxin is 30–50 h, corresponding to
a 10-day washout. Medication was taken following an
overnight fast of C8 h, and no food or liquid (excluding
water) was allowed until 4 h post-dose, when a standard-
ised meal was served. All other oral drugs (other than trial
drugs) were disallowed ±4 h during dosing visits. The
dosing conditions, schedule and washout period in both
studies ensured there was no effect of food or drug–drug
interaction between the two drugs evaluated in each study.
Single doses of warfarin (Coumadin 25 mg, dispersed as
five tablets of 5 mg; anticipated ratio of 50% S-warfarin
and 50% R-warfarin), atorvastatin (one tablet of Hennig
40 mg) and digoxin (two tablets of Digacin 0.25 mg)
were given before and with semaglutide treatment. Met-
formin was dosed twice daily (one tablet of Glucophage
500 mg) in two periods of 3.5 days before and with
semaglutide, to obtain steady-state conditions and min-
imise the potential of within-subject variation in metformin
bioavailability [20].
The selected dose range of the study drugs was as rec-
ommended for standard therapeutic maintenance treatment,
and subjects were dose escalated to semaglutide 1.0 mg
steady state to investigate potential interactions at the
highest intended treatment dose. Drug–drug interactions
were also evaluated near the expected time of maximum
semaglutide concentration at steady state. Adherence to
specific food restrictions was also required, prior to the PK
dosing days, to avoid potential interactions with CYP-
metabolising enzymes. Both studies were conducted in
compliance with the International Conference on Har-
monisation Good Clinical Practice guidelines [25] and the








































Fig. 1 Study design. Atorv atorvastatin, Dig digoxin, Met metformin,
Ortho-OH ortho-hydroxylated atorvastatin metabolite, Para-OH para-
hydroxylated atorvastatin metabolite, SS steady state, War warfarin.
Asterisk Metformin was administered 3.5 days prior to the metformin
pharmacokinetic sampling visit. Dagger Administered 48 h after the
fifth dose of semaglutide 1.0 mg. Double dagger Administered 48 h
after the sixth dose of semaglutide 1.0 mg. Section sign In Study 2,
follow-up visit was at visit 12. The subjects received metformin and
warfarin in Study 1, and atorvastatin and digoxin in Study 2
Semaglutide Co-Administration with Metformin, Warfarin, Atorvastatin or Digoxin
2.3 Endpoints and Assessments
The primary objective was to evaluate whether
semaglutide 1.0 mg at steady state altered the steady-
state exposure of metformin and the single-dose expo-
sure of warfarin, atorvastatin and digoxin. Primary
endpoints were assessed before and with semaglutide
treatment and included: area under the plasma concen-
tration–time curve (AUC) for metformin during a dosing
interval 0–12 h after the last of seven repeated doses;
AUC for S- and R-warfarin 0–168 h after a single dose
of warfarin; AUC for atorvastatin 0–72 h after a single
dose of atorvastatin; and AUC for digoxin 0–120 h after
a single dose of digoxin.
Secondary endpoints included: maximum plasma
concentration (Cmax) and time to Cmax (tmax) for met-
formin, S- and R-warfarin, atorvastatin and digoxin;
incremental area under the international normalised ratio
(INR) curve for warfarin 0–168 h (iAUCINR,0–168 h);
maximum observed INR response; time to maximum
observed INR response; and the Cmax, tmax and t1/2 of
semaglutide at steady state. Safety and tolerability were
also assessed.
Samples for PK analysis were collected at specific
timepoints for each drug, all before and with semaglutide.
Pharmacokinetic sampling for metformin was performed
from pre-dose to 30 h post-dose (after the last of seven
doses administered over 3.5 days); for warfarin from pre-
dose to 168 h post-dose; for atorvastatin from pre-dose to
72 h post-dose; and for digoxin from pre-dose to 120 h
post-dose. Semaglutide sampling was at regular time
intervals ranging between 0 and 840 h after the last dose of
1.0 mg of semaglutide.
Plasma concentrations of metformin, warfarin and
semaglutide were measured by a validated liquid chro-
matography-tandem mass spectrometry method after pre-
cipitation of the plasma protein. Atorvastatin and digoxin
were measured by high-performance liquid chromatogra-
phy with mass-spectrum detection. All known active
metabolites of atorvastatin were measured, while metabo-
lites with unconfirmed activity were not. The INR was
determined from prothrombin time using a validated assay
method.
Safety and tolerability assessments included treat-
ment-emergent adverse events (AEs) and hypogly-
caemic episodes. Hypoglycaemia was evaluated
according to the American Diabetes Association clas-
sification [27]. Probable symptomatic hypoglycaemia
was defined as an episode during which symptoms of
hypoglycaemia were not accompanied by a low plasma
glucose determination but presumably caused by a low
plasma glucose level [27].
2.4 Analytical and Statistical Methods
2.4.1 Determination of Sample Size
For 20 completing subjects, Study 1 was calculated to have
a statistical power of 89%, assuming ratios of 0.97, and
within-subject standard deviations on the log scale of 0.1
for warfarin and 0.2 for metformin. For 24 completing
subjects, Study 2 was calculated to have a statistical power
of 90%, assuming ratios of 0.95, and within-subject stan-
dard deviations on the log-scale of 0.17 for atorvastatin and
0.18 for digoxin. For both studies, the statistical power was
calculated using two one-sided t tests with a 5% signifi-
cance level and a pre-specified interval of (log [0.80]; log
[1.25]).
2.4.2 Definition of Analysis Sets and Statistical Analysis
of Endpoints
Pharmacokinetic, PD and safety assessments were based on
all subjects who received one or more doses of trial
product. For PK and PD analysis, subjects had to have
evaluable profiles before and with semaglutide treatment.
The primary endpoints were calculated using standard
non-compartmental methods, by means of the linear
trapezoidal method on the observed concentrations, using
actual sampling timepoints. The AUCs were analysed
using linear normal models, based on the log-transformed
values, including semaglutide exposure (before or with)
and subject as fixed effects. Estimated differences in
exposure are presented on the original scale as ratios with
90% confidence intervals (CIs). No clinically significant
effect on AUC was concluded if the 90% CI was within the
interval of 0.80–1.25.
Maximum plasma concentration for metformin, S- and
R-warfarin, atorvastatin and digoxin was analysed using
the same model as that for the primary endpoints. For
metformin and warfarin, the 90% CIs for ratios were
evaluated against the pre-specified interval in the same way
as for the primary endpoints. The PD endpoint for INR
(iAUC) was also analysed using the same model as that for
the primary endpoints. Adverse events were coded using
Medical Dictionary for Regulatory Activities version 17.0
and summarised descriptively [28].
3 Results
3.1 Baseline Characteristics
Baseline characteristics were similar between the two
studies (Table 1); 24 subjects were exposed to metformin
H. Hausner et al.
and warfarin in Study 1, and 31 subjects to atorvastatin and
digoxin in Study 2. One subject withdrew from Study 1
after the first dose of 0.25 mg of semaglutide (consent
withdrawal). One subject was excluded from the PK and
PD analyses in Study 1 owing to non-compliance with
semaglutide administration and self-induced vomiting
shortly after warfarin dosing. Five subjects withdrew from
Study 2 (four because of AEs; one because of consent
withdrawal).
3.2 Pharmacokinetics
The mean PK profiles for all drugs tested are shown in
Fig. 2a–d. The estimated exposure ratios (ERs) for AUC and
Cmax for all concomitant medications are shown in Table 2
and Fig. 3. Overall, the 90% CIs of the ERs for AUC for all
concomitant medications were within the pre-specified
interval. The Cmax values for metformin, S-warfarin and
R-warfarin were slightly reduced when co-administered with
semaglutide 1.0 mg; however, these were well within the
pre-specified interval (Table 2). The Cmax for atorvastatin
was reduced by 38% (ER 0.62) when co-administered with
semaglutide, but was similar for digoxin.
The tmax values for metformin and t1/2 of metformin, S-
and R-warfarin, and digoxin were comparable when
administered before and with semaglutide (data not
shown). The observed tmax for warfarin was delayed with
semaglutide treatment (median tmax 3.0 vs. 1.0 h). Like-
wise, Cmax occurred later for atorvastatin with semaglutide
treatment, vs. before semaglutide treatment (median tmax
2.0 vs. 0.7 h).
CYP2C9 genotyping was performed to account for any
variability in the pharmacokinetics and pharmacodynamics
of CYP2C9-metabolised S-warfarin. Results of this
analysis showed an even distribution between intermediate
and extensive metabolisers (Table 1). The PK properties of
semaglutide observed in these studies (Cmax
43.1–48.6 nmol/L; median tmax 36 h; and t1/2 156–160 h)
are in line with those from previous studies [12], indicating
a high level of compliance with the treatment regimen
during the trial.
3.3 Effect of Semaglutide on International
Normalised Ratio Response to Warfarin
For warfarin, the INR iAUC and maximum INR response
were similar before and with semaglutide treatment [re-
sponse ratio 1.05 (90% CI 0.87–1.28) and 1.04 (90% CI
0.99–1.10), respectively; Fig. 4]. The median time to
maximum INR response was 48 h (range 36–60 h) before
semaglutide and 36 h (range 36–60 h) with semaglutide
(Fig. 4).
3.4 Safety
No deaths or serious AEs were reported. In Study 1, 121
treatment-emergent AEs were reported in 23 of 24 sub-
jects: all were mild (n = 106) or moderate (n = 15). No
withdrawals because of AEs were reported. In Study 2, 271
treatment-emergent AEs were reported in 28 of 31 sub-
jects; most were mild (n = 209) or moderate (n = 59).
Three severe AEs were reported (one each during ator-
vastatin-only treatment, semaglutide-only treatment, and
digoxin co-administered with semaglutide treatment), and
were attributed to atrioventricular block, nausea and diar-
rhoea, respectively. Adverse events leading to withdrawal
were reported in two subjects during atorvastatin-only




Study 1 Study 2
Number of subjects 23 31
Mean age, years (min.; max.) 44 (26; 55) 45 (25; 55)
Sex, n (%)
Female 10 (43.5) 16 (51.6)
Male 13 (56.5) 15 (48.4)
Race, n (%)
White 23 (100) 31 (100)
Mean body weight, kg (min.; max.) 80.0 (62.9; 94.0) 75.4 (53.6; 102.4)
Mean height, m (min.; max.) 1.75 (1.61; 1.87) 1.73 (1.54; 1.90)
Mean BMI, kg/m2 (min.; max.) 26.2 (23.0; 29.7) 25.2 (20.4; 29.8)
Phenotype CYP2C9, EM, n (%) 12 (52.2)
Phenotype CYP2C9, IM, n (%) 11 (47.8)
Phenotype CYP2C9, PM, n (%) 0 (0)
BMI body mass index, CYP cytochrome P450, EM extensive metaboliser, IM intermediate metaboliser,
max. maximum, min. minimum, PM poor metaboliser
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Fig. 2 Mean pharmacokinetic
profiles of metformin (a),
S-warfarin* (b), atorvastatin
(c) and digoxin (d) before and
with semaglutide treatment.
Reference line for the lower
limit of quantification. Values
below the lower limit of
quantification are imputed.
Asterisk R-warfarin curves are
not included here but followed a
similar pattern to the S-warfarin
curves
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two subjects during semaglutide-only treatment (both GI
AEs).
The most common AEs across both studies were GI
related (Table 3). Gastrointestinal-related AEs were
observed during treatment with both semaglutide alone and
with all four concomitant medications: nausea was the
most frequent. Overall, AEs reported with semaglutide and
co-administered medication were comparable to those
reported during semaglutide-only treatment. No bleeding
was observed with warfarin.
No severe hypoglycaemic episodes were reported. In
Study 1, there was one probable symptomatic hypo-
glycaemic episode during semaglutide-only treatment. In
Study 2, four hypoglycaemic episodes were reported: one
asymptomatic episode during semaglutide-only treatment,
and three probable symptomatic episodes (atorvastatin
alone, n = 1; semaglutide alone, n = 2).
4 Discussion
Drug–drug interaction studies are needed to identify
exposure, safety and tolerability issues related to the con-
comitant use of typically prescribed oral medications. In
these studies, the absorption pharmacokinetics of four
separately administered oral drugs was assessed before and
with semaglutide treatment, to evaluate the potential for
semaglutide to affect the absorption of co-administered
oral drugs. For all of the concomitant medications
Metformin, AUC (0–12 h)
Cmax
S-warfarin, AUC (0–168 h)
Cmax
R-warfarin, AUC (0–120 h)
Cmax
Digoxin, AUC (0–120 h)
Cmax






Fig. 3 Estimated exposure
ratios for metformin, warfarin,
atorvastatin and digoxin before
and with semaglutide treatment.
Estimated ratios, before vs. with
semaglutide treatment and 90%
confidence intervals are shown.
AUC area under the plasma
concentration–time curve, Cmax
maximum plasma concentration
(Cmax limits for atorvastatin and
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Fig. 4 Mean international normalised ratio (INR) profile for warfarin
Table 2 Estimated AUC and
Cmax ratios for metformin,
S-warfarin, R-warfarin,
atorvastatin and digoxin before
and with semaglutide treatment
Medication AUC Cmax
Estimated ratio 90% CI Estimated ratio 90% CI
Metformin (n = 22) 1.03 0.96–1.11 0.90 0.83–0.98
S-warfarin (n = 22) 1.05 0.99–1.11 0.91 0.85–0.98
R-warfarin (n = 22) 1.04 0.98–1.10 0.93 0.87–1.00
Atorvastatin (n = 26) 1.02 0.93–1.12 0.62 0.47–0.82
Digoxin (n = 26) 1.02 0.97–1.08 0.93 0.84–1.03
AUC area under the plasma concentration–time curve, CI confidence interval, Cmax maximum plasma
concentration
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evaluated in this study, the ratio for total exposure (AUC)
was within the pre-specified limits (0.80–1.25), suggesting
that there are no drug–drug interactions between
semaglutide and the co-administered drugs.
Overall, AUCs were similar for digoxin and warfarin
with ratios between AUCs close to 1.0. Peak plasma con-
centrations for digoxin were similar, and slightly reduced
for warfarin, when co-administered with semaglutide;
however, these were within pre-specified limits. Likewise,
metformin and atorvastatin plasma profiles had AUC ratios
close to 1.0 and shared the same characteristics of being
slightly right-shifted and with lowered maximum concen-
trations (10 and 38%, respectively).
The effect of semaglutide on gastric emptying has been
assessed by the paracetamol absorption technique during a
standardised meal [13, 29, 30]. The results indicate that
there is a minor delay of gastric emptying during the early
postprandial phase for subjects when treated with
semaglutide, compared with placebo, but there is no overall
effect on gastric emptying over a 5-h postprandial period
[13]. A delayed gastric emptying may result in slower
absorption, delayed tmax and decreased Cmax of concomi-
tant oral drugs, which would account for the trends
observed in this and previous studies with GLP-1RAs
[15, 31, 32]. Metformin is primarily absorbed in the small
intestine (metformin concentration in the jejunum is
30–300 times higher than in plasma), thus a delayed gastric
emptying might result in slower absorption [18]. In line
with data reported for dulaglutide [33], the overall
absorption of metformin was unchanged when co-admin-
istered with semaglutide, while the delayed gastric emp-
tying resulted in a somewhat prolonged absorption, and
thereby a slightly lowered Cmax.
The absorption pharmacokinetics of atorvastatin also
appeared to be influenced by the GI transit time, showing a
slightly prolonged absorption rate and a lowered Cmax;
nevertheless, this did not influence overall exposure. The
observed effect of semaglutide on peak concentration of
atorvastatin was assessed to be of unlikely clinical rele-
vance as the efficacy of atorvastatin has been shown to be
poorly correlated with Cmax [34]. Similar absorption
pharmacokinetics on Cmax have been observed for co-ad-
ministration of atorvastatin with liraglutide [31], dulaglu-
tide [33] and lixisenatide [35]. As with semaglutide, gastric
emptying is decreased during the first hour after a meal
with liraglutide [36]. On this basis, Cmax was expected to
be lower with semaglutide. In contrast, delayed gastric
emptying gives medications with low solubility or disso-
lution rate (such as digoxin) additional time to dissolve,
which may increase exposure. This effect was observed for
overall and peak exposure of co-dosing with albiglutide
[15], while co-administration of liraglutide 1.8 mg lowered
digoxin exposure [31]. However, for semaglutide and other
GLP-1RAs, an unchanged exposure of concomitant
digoxin has been observed [32, 33].
No clinically relevant change in the anticoagulant effect
of warfarin was observed when it was co-administered with
semaglutide, as measured by changes in INR. This finding,
in addition to the observation that PK profiles of S- and
R-warfarin are unaffected, supports the absence of a drug–
drug interaction between semaglutide and warfarin. The
INR of warfarin has also been shown to be unaffected by
albiglutide administration [15]. A small change in the INR
of warfarin was observed with exenatide administration,
but was not clinically significant [32].
Overall, no new safety or tolerability issues related to
semaglutide, either when administered alone or when co-
administered with metformin, warfarin, atorvastatin or
digoxin, were identified in these studies. On the basis of the
results, no clinically relevant change in the tolerability and
safety profiles of semaglutide, metformin, warfarin, ator-
vastatin or digoxin is anticipated when co-dosing at
steady state.
In general, these findings confirm that semaglutide has a
minor effect on the absorption of the drugs investigated, a
group of drugs with various degrees of solubility, perme-
ability and narrow therapeutic windows, and are consistent
with results from previous studies with GLP-1RAs
[31, 37–40]. The overall risk of clinically relevant inter-
actions with semaglutide is therefore considered low, in the
case of compounds that share the same properties as these
studied drugs, including compounds with narrow thera-
peutic indexes; thus no dose adjustment in the clinical
setting should be required.
5 Conclusion
Semaglutide treatment did not affect the overall exposure
or Cmax of metformin, warfarin, atorvastatin or digoxin to a
clinically relevant degree. In addition, semaglutide was
well tolerated in combination with these drugs, and no new
safety issues were identified. Therefore, these drugs can be
used without dose adjustment when prescribed concomi-
tantly with semaglutide.
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